On March 16, 2020 Biocure Technology Corp. ("CURE" or the "Company") (CSE:CURE; OTCQB: BICTF) BiocurePharm, Korea ("BPK"), a subsidiary of Biocure Technology Inc. ("CURE") reported that it has closed its non-brokered private placement through its Korean Subsidiary BiocurePharm, Korea ("BPK"), BPK has issued 5,990 shares at 12.639 CAD per share for gross proceeds of $75,707 (Press release, Biocure Technology, MAR 16, 2020, View Source [SID1234628752]). All dollar values are based on the published Exchange Rate of CAD0.001149/KRW1 on March 13, 2020, Bank of Canada. After the issuance of new BPK shares, CURE holds now 94.32% interest in BPK.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The net proceeds from the non-brokered private placement are intended to be used for general working capital and clinical trial of CAR T in Korea.